LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study

T. Mazard,F. Ghiringhelli, A. Winter,C. de la Fouchardiere, D. Botsen, T. André, J. Vanbockstael,M. Dos Santos, J. Martin-Babau, Y. Rinaldi,L. Evesque, S. Ellis, C. Gavoille,D. Smith, M. Fonck,D. Sefrioui, V. Pezzella, S. Nougaret,A.R. Thierry, O. Bouche

Annals of Oncology（2023）

引用 0|浏览6

暂无评分

关键词

unresectable metastatic colorectal cancer,colorectal cancer,lba30 panitumumab,tumor status,wild-type,panirinox-ucgi

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要